+39 02 610346.1 - info@newron.com

Latest press releases

  • 11Apr
    Valeo Pharma and Zambon form partnership for Parkinson’s disease treatment Xadago® (safinamide) in Canada

  • 10Apr
    ZAMBON LAUNCHES XADAGO® (safinamide) IN PORTUGAL For patients With mid- to late-stage Parkinson’s Disease

     

  • 5Apr
    Meiji Seika and Eisai enter into a collaboration for the development and commercialization of safinamide in Parkinson’s disease for Japan and Asia

  • 28Mar
    Newron Shareholders Confirm Company Management

     

  • 25Mar
    Newron presents encouraging detailed results of its Phase IIa study with Evenamide in patients with schizophrenia

     

  • 21Mar
    FDA APPROVES XADAGO® (SAFINAMIDE) FOR PARKINSON’S DISEASE (PD) PATIENTS

     

View All

Newron share price

Events

  • 20Sep
    Investora 2017

    Sept. 20-21, 2017 - Zurich, CH

  • 6Jun
    Jefferies 2017 Global Healthcare Conference

    June 6-9, 2017 at the Grand Hyatt in New York City

  • 22May
    Bio€quity Europe 2017

    May 22-23 - Paris, France

View Event Calendar